Organization · Venture Capital
Decheng Capital
Decheng Capital is a venture capital firm specializing in early-stage life science companies and growth-stage healthcare companies, with offices in Silicon Valley, Shanghai, and New York. The firm focuses on cross-border investments in the healthcare sector.
Overview
What Decheng Capital does
What Decheng Capital is
Decheng Capital is a venture capital firm specializing in early-stage life science companies and growth-stage healthcare companies, with offices in Silicon Valley, Shanghai, and New York. The firm focuses on cross-border investments in the healthcare sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2012
- Approximate age
- About 14 years
- Structured capabilities
- Funder
- Last reviewed
- March 19, 2026
Official channels
Find Decheng Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Decheng Capital as a funder
Investment thesis
Decheng Capital focuses on cross-border investments in life sciences, leveraging China's healthcare growth alongside US innovation. The firm targets early-stage revolutionary technologies and growth-stage healthcare companies, aiming to capitalize on strong relationships with major pharmaceutical acquirers.
Focus narrative
Decheng Capital invests primarily in early-stage life science companies and growth-stage healthcare companies. The firm focuses on sectors such as biopharma, diagnostics and tools, medical devices, and healthcare services, aiming to support transformative technologies that can improve patient outcomes and healthcare delivery.
Value beyond capital
Decheng Capital adds value to its portfolio companies through strategic support, leveraging its extensive network of industry contacts, and providing insights into market trends and opportunities. The firm's deep understanding of both the US and Chinese healthcare landscapes enables it to facilitate cross-border collaborations and partnerships.
Terms and economics
- Typical check
- $1,000,000–$70,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Digital Health · Medical Devices · Pharma Tech
- Regions
- Asia · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Acelyrin, Arcus Biosciences, CG Oncology, ARMO Biosciences, Checkmate Pharmaceuticals, and GeneWeave
Portfolio context
Notable portfolio companies include: 3SBio: IPO in 2015 (HKSE: 1530) Aadi Bioscience: IPO in 2021 (NASDAQ: AADI) Cellares: Recently raised $255M Series C to launch an integrated development and manufacturing organization. Mammoth Biosciences: Engaged in a gene editing deal worth $100M with Regeneron. Prometheus Biosciences: Acquired by Merck for $10.8 billion.
Common questions
What to know about Decheng Capital
Upseed classifies Decheng Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 19, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.